Itrac (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. Without ergosterol, the fungal cell membrane becomes unstable, leading to impaired growth and eventual cell death, thereby clearing the infection.

The dosage of Itrac is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Only a qualified health professional should set the dose and duration.

Safety data for itraconazole in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a healthcare provider.

To request Itrac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itrac belongs to the azole class, which generally offers oral convenience and broad-spectrum activity against yeasts and molds. Compared with polyenes (e.g., amphotericin B), azoles have fewer infusion‑related reactions but may have more drug‑interaction potential due to CYP3A4 inhibition.

Itrac should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain potency throughout its shelf life.

Itrac is taken orally, usually with a full glass of water. The tablet or capsule should be swallowed whole and not chewed or crushed, unless the prescriber provides specific instructions for a different formulation.

Serious risks include hepatotoxicity, which may present as elevated liver enzymes or hepatitis, and cardiac failure, especially in patients with pre‑existing heart conditions. Severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome can also occur and require immediate medical attention.

Patients with known hypersensitivity to itraconazole or any azole antifungal should not use Itrac. It is also contraindicated in individuals with uncontrolled heart failure, severe liver impairment, or those taking medications that strongly induce CYP3A4 without appropriate monitoring.